The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

OKYO Insider Trading (OKYO Pharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £354,679.73
Insider Selling (Last 12 Months): GBX 0

OKYO Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at OKYO Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OKYO Pharma Share Price & Price History

Current Price: GBX 2.75
Price Change: +0.30 (1.20%)
As of 08/12/2022 01:00 AM ET

This chart shows the closing price history over time for OKYO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

OKYO Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2022Willy Jules SimonInsiderBuy55,991GBX 3£1,679.73
5/19/2022Gabriele CerroneInsiderBuy5,800,000GBX 6£348,000
1/26/2022Gabriele CerroneInsiderBuy100,000GBX 5£5,000
See Full Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for OKYO Pharma (LON:OKYO)

OKYO Pharma logo
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Read More on OKYO Pharma

Today's Range

Now: GBX 2.75
Low: 2.75
High: 2.80

50 Day Range

MA: GBX 2.77
Low: 2.50
High: 3.30

52 Week Range

Now: GBX 2.75
Low: 2.50
High: 9

Volume

107,150 shs

Average Volume

251,513 shs

Market Capitalization

£38.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of OKYO Pharma?

OKYO Pharma's top insider shareholders include:
  1. Gabriele Cerrone (Insider)
  2. Willy Jules Simon (Insider)
Learn More about top insider investors at OKYO Pharma.
Potential 500% Return From A Unique $1 Asset?
Millions are rushing towards life at “Ground Zero”. 

A frightening new financial reality that has the potential to erase the wealth of millions. It’s largely avoidable if you know what to look for.

It all hinges on a single $1 asset that skyrockets during strange times like these. 

Discover it now
>>>